Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Approaches to aggressive B-cell lymphomas in less fit patients
Nancy L. Bartlett
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Approaches to aggressive B-cell lymphomas in less fit patients'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Comorbidity
100%
Aggressive B-cell Lymphoma
100%
Unfit Patients
100%
Fit Patients
100%
Anthracyclines
50%
Frailty
25%
Performance Status
25%
Dose Reduction
25%
Newly Diagnosed
25%
Cardiovascular Disease
25%
Bispecific Antibody
25%
First-line Therapy
25%
Oncologists
25%
Effective Strategies
25%
Novel Antibodies
25%
Median Survival
25%
Antibody-drug Conjugate
25%
Less Toxic
25%
Performance Improvement
25%
Metastatic Tumor
25%
Anthracycline Therapy
25%
Cardio
25%
Patient Fitness
25%
Severe Toxicity
25%
Chemotherapy Cycles
25%
First Cycle
25%
Palliative Therapy
25%
Advanced Dementia
25%
Co-management
25%
Gerontologist
25%
Poorly Controlled Diabetes Mellitus
25%
Endocrinologists
25%
Toxic Agents
25%
Medicine and Dentistry
B-Cell Lymphoma
100%
Comorbidity
100%
Anthracycline
75%
Steroid
50%
Frailty
25%
Cardiovascular Disease
25%
Decision Making
25%
Bispecific Antibody
25%
Symptomatic Treatment
25%
Solid Malignant Neoplasm
25%
Oncologist
25%
Antibody-Drug Conjugate
25%
Diabetes Mellitus
25%
Spine
25%
Drug Dose Reduction
25%
Endocrinologist
25%
Toxic Agent
25%
Chemotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
B Cell Lymphoma
100%
Comorbidity
100%
Anthracycline
75%
Steroids
50%
Bispecific Antibody
25%
Solid Malignant Neoplasm
25%
Diabetes Mellitus
25%
Chemotherapy Regimens
25%
Frailty
25%
Antibody Drug Conjugate
25%
Toxic Agent
25%
Cardiovascular Disease
25%